Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12467471 | 1.00 | NOS2 (0.42) | NOS2TACR1LMNATAS2R14GPR139 | |
| SCHEMBL12402683 | 0.92 | TACR1 (0.47) | NOS2TACR1LMNAGPR139IDO1 | |
| SCHEMBL12402681 | 0.92 | TACR1 (0.47) | NOS2TACR1LMNAGPR139IDO1 | |
| SCHEMBL12154028 | 0.92 | TACR1 (0.47) | NOS2TACR1LMNAGPR139IDO1 | |
| SCHEMBL12154055 | 0.81 | NOS2 (0.47) | NOS2LMNAMEN1KMT2A | |
| SCHEMBL3091964 | 0.74 | NOS2 (0.60) | NOS2LMNAMAPT | |
| SCHEMBL6901975 | 0.74 | NOS2 (0.60) | NOS2LMNAMAPT | |
| SCHEMBL6898289 | 0.74 | NOS2 (0.60) | NOS2LMNAMAPT | |
| SCHEMBL3091960 | 0.74 | NOS2 (0.60) | NOS2LMNAMAPT | |
| SCHEMBL6901967 | 0.74 | NOS2 (0.60) | NOS2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985880-B2 | Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl) alkylamine N-monoalkyl derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | NAT1, MAOA, HNMT | NOS2 211/4885TACR1 3349/4885LMNA 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.